Latest International AIDS Vaccine Initiative Stories
ATLANTA, May 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta (ARCA) has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc. Although the GeoVax vaccines are currently being studied for HIV prevention, this is the first study using the...
SMYRNA, Ga., May 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is spotlighted on an interactive map posted on the website of Inc. magazine. The map, created by Nitasha Tiku and April Joyner, is headlined "Incubation Nation: Where Great Ideas Are Born." Tiku and Joyner write: "Spun out of university research labs or started by local entrepreneurs trying to supercharge their...
NEW YORK, May 17 /PRNewswire-USNewswire/ -- For more than a decade, researchers and advocates have marked HIV Vaccine Awareness Day with varying degrees of hope, cynicism and despair. This year, in large part because of the results of the Thai Prime-Boost vaccine study, there is greater cause for hope than ever before and a renewed sense of urgency to transform this hope into a reality. In September 2009, the world's largest AIDS vaccine trial to date showed the first evidence that an...
SMYRNA, Ga., May 17 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will speak at a symposium devoted to the development of HIV/AIDS vaccines to be held at the New York Academy of Sciences in New York City on Wednesday, May 19. The one-day symposium, titled "HIV/AIDS: Vaccines and alternate strategies...
ATLANTA, April 29 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is participating in the BIO International Convention (BIO2010) taking place May 3-6, 2010 in Chicago, IL at McCormick Place. This event, hosted by the Biotechnology Industry Organization (BIO), will feature high-level industry leaders discussing public policy issues of critical importance to all segments of the...
ATLANTA, April 27 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, has issued a letter to its shareholders and has added a question and answer section to its website. To view the shareholder letter in its entirety, please follow this link to the Company's website: www.geovax.com. In the letter, GeoVax Labs President and CEO Robert T. McNally, PhD, updates shareholders on the Company's...
NEW YORK and GAITHERSBURG, Md., April 22 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement. Lentigen's technology relies on a synthetic version of a virus related to HIV that has been...
SMYRNA, Ga., March 30 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and Drug Administration) to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The company will begin a non-blinded study in HIV infected individuals who started...
SEATTLE, March 24 /PRNewswire/ -- Clinic sites in 13 cities across the U.S. are looking for a total of 1,350 HIV-negative gay men to participate in the latest HIV vaccine study from the HIV Vaccine Trials Network (HVTN). And they're using social media to help reach these individuals where they are, which, these days, is increasingly online. The HVTN, internationally headquartered at Fred Hutchinson Cancer Research Center in Seattle, is running a series of ads on Facebook, seeking men who...
SMYRNA, Ga., March 22 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), a thirteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency. "GeoVax Labs has outlined several important initiatives for 2010, and we are confident that IRG will have a...
